# CLINICAL, BIOCHEMICAL AND MOLECULAR CHARACTERISTICS OF THE PATIENTS WITH NONCLASSICAL CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY IN CROATIA

<sup>1</sup>M.Dumic, <sup>2</sup>N.Krnic, <sup>3</sup>V.Kusec, <sup>4</sup>Z.Grubic, <sup>4</sup>K.Stingl, <sup>5</sup>T.Yuen, <sup>2</sup>K.Dumic Kubat, <sup>6</sup>V.Skrabic, <sup>5</sup>M.I.New

<sup>1</sup>University of Zagreb Medical School, Zagreb, Croatia; <sup>2</sup>Department of Pediatric Endocrinology and Diabetes, Clinical Hospital Centre Zagreb, Zagreb, Zagreb, Croatia; <sup>3</sup>Endocrinological Laboratory, Department of Laboratory Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia; <sup>4</sup>Tissue Typing Centre, Department of Laboratory Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia; <sup>5</sup>Steroid Disorder Program, Department of Pediatric Endocrinology, Mount Sinai School of Medicine, New York, NY USA; <sup>6</sup>Department of Pediatrics, Clinical Hospital Centre Split, Split, Croatia

### **OBJECTIVES**

BACKGROUND: Nonclassical congenital adrenal hyperplasia (NCCAH) due to mild 21-hydroxylase deficiency is caused by mutations of the *CYP21A2* gene located on chromosome 6p21.3. AIMS AND OBJECTIVES: To determine cut-off for basal and stimulated 17-hydroxyprogesterone (17-OHP) levels, to evaluate *CYP21A2* gene mutations frequency among Croatian NCCAH patients, to determine correlation between 17-OHP levels and genotype and to evaluate correlation between 17-OHP levels, *CYP21A2* gene mutations and phenotype.




Figure 1. Sensitivity and specificity of basal 17-OHP levels in patients with NCCAH using Receiver Operating Characteristic Curve




Figure 2. Sensitivity and specificity of stimulated 17-OHP levels in patients with NCCAH using Receiver Operating Characteristic Curve

# PATIENTS AND METHODS

A cohort of 40 fully genotyped patients (31 unrelated) with NCCAH (29 female/11 male) was studied. Seven female and 9 male patients were discovered through family studies. All subjects were evaluated for signs of hyperandrogenism. Basal levels of 17-OHP were determined in all patients and ACTH-stimulated 17-OHP levels were measured in 34/40 patients.

### RESULTS

At diagnosis, 73.47% of patients were symptomatic. The commonest symptoms were precocious pubic hair development and advanced bone age.

The 17-OHP cut-off levels of best sensitivity and specificity in our cohort of patients are 8.8 nmol/l for baseline and 39.2 nmol/l for ACTH stimulated 17-OHP levels (Figure 1. and 2.). Only one patient had baseline 17-OHP levels below 6 nmol/l. Among 40 fully genotyped patients, 12 patients carried two "mild" *CYP21A2* mutations, 27 were compound heterozygotes for one "mild" and one "moderate/severe" mutation, and 1 patient had one "moderate" and one "severe" mutation (I172N/ I2G). The commonest mutation in our study group is V281L (85,0%).

No corrrelation was found between phenotype and basal and stimulated 17-OHP levels. There was no statistically significant difference between basal and stimulated 17-OHP leves among symptomatic and asymptomatic patients (p=0,786 for basal and p=0,531 for stimulated 17-OHP levels). Genotype severity did not correlate with phenotype or basal and stimulated 17-OHP levels.

# **CONCLUSIONS**

Patients with basal 17-OHP levels above 8.8 nmol/l should be further evaluated for NCCAH. Phenotype and 17-OHP levels do not correlate with severity of genotype suggesting that modifier factors may modulate phenotypic expression. Thus molecular analysis of *CYP21A2* gene should be done in all patients, especially due to high frequency of patients with one "moderate/severe" mutation. Considering the high incidence of heterozygotes in the general population, it is important to genotype the partners of the patients with one severe mutation to offer genetic counseling.

### References

- •Bidet M et al. Clinical and Molecular Characterization of a Cohort of 161 Unrelated Women with Nonclassical Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and 330 Family Members. J Clin Endocrinol Metab 2009;94(5): 1570-1578.
- Dumic M et al. Nonclassic 21-Hydroxylase Deficiency in Croatia. J Pediatr Endocrinol Metab 2004;17(2):157-64.
- •Ghizzoni L et al. Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche. Eur J Endocrinol 2011;165(2):307-314.
- New MI. Extensive clinical experience: nonclassical 21hydroxylase deficiency. J Clin Endocrinol Metab 2006;91(11): 4205-4214.
- •Speiser PW et al. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship betweem genotype and phenotype. Mol Genet Metab 2000;71:527-534.



